News Release

JournalArticle Cites HemoVoid™ in Multi-Omics Analysis of Red Blood Cellsin Thalassemia

MONMOUTHJUNCTION, NJ, March6, 2025-- Biotech Support Group reports on a research article describing thesimplicity and efficiency of their HemoVoid™ technology forenriching erythrocyte low abundance proteins, in order to assessdysregulated pathways associated with Thalassemia severity. 

Thecitation is:

Mitra,Nibedita, et al. "Multi-OmicsAnalysis of Red Blood Cells Reveals Molecular Pathways UnderlyingThalassemia Severity Beyond Globin Gene Mutations." medRxiv (2025):2025-02.

Hemoglobinopathiesare the most common monogenic genetic disorders. Clinical severityother than mutational effects are still unknown. This study aims toidentify dysregulated molecular pathways in red blood cellscontributing to thalassemia severity. In the Methods section forSample Preparation for RBC Proteomics Study, the article states “A75µL suspension of RBC cells was used to prepare RBC lysate.Proteins were extracted with RIPA buffer, and hemoglobin was depletedusing the HemoVoid kit”. A total of 430 differentially abundantproteins were identified between the two patient groups. The criticalprotein signatures and their target pathways are as follows: 1.Increased PIP4K2A Proteins: This leads to a reduction in gamma globinlevels. 2. Altered Expression of snRNA/snRNP Complex HEXIM1 and OthersnRNPs (SNRNP70, SF3B4, WDR77): These changes impact transcription,translation, and aberrant splicing 3. Reduced Levels of FunctionalAutophagy Regulatory Proteins (ATG2B, ATG4B, ATG5, FOXO3). 4.Decreased Abundance of Functional Hsp70 Heat Shock Chaperone Proteins(HSPA2, HSPA14). 5. Increased Levels of Iron Regulatory Proteins(FTH1, FTL) in TDT Patients. 

“It’svery rewarding to see that for Hemoglobin removal, HemoVoid™ was anessential product to enrich the red blood cell proteome for thisstudy. Many references now validate the use of HemoVoid™ as anefficient method to deplete Hemoglobin in order to enrich and analyzelow abundance sub-proteomes.”, states Swapan Roy, Ph.D., Presidentand Founder of Biotech Support Group.

Formore information on HemoVoid™, visit:

http://www.biotechsupportgroup.com/HemoVoid-Hemoglobin-Depletion-From-Erythrocytes-p/hvk.htm

Formore information of all of our Hemoglobin removal products, visit:

https://www.biotechsupportgroup.com/Hemoglobin-Removal-s/312.htm

AboutBiotech Support Group LLC

Convergingwith cultural and technological disruptions forthcoming inhealthcare, Biotech Support Group develops methods for cost effectiveand efficient sample prep essential for expanding proteomic analysis.Following a tiered business strategy, the company continues itsgrowth in the consumable research products area. For this market, keyproducts include: AlbuVoid™ and AlbuSorb™ PLUS foralbumin & IgG depletion, Cleanascite™for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobinremoval, and NRicher™ for low abundance, family specific, andtargeted proteome enrichment. For more information, go tohttp://www.biotechsupportgroup.com

Forbusiness development contact: Matthew Kuruc
732-274-2866[email protected]

Keywords

Thalassemia,RBC lysates, Hemoglobin depletion, erythrocyte proteomics, HemoVoid™